Recombinant Human Papillomavirus Type 16/18 Bivalent Vaccine (Hansenula polymorpha,Jiangsu RecBio Technology）

重组人乳头瘤病毒16/18型二价疫苗（汉逊酵母，江苏瑞科生物）

Report date: 2025/12/11 09:46:41

Base Information

Drug NameRecombinant Human Papillomavirus Type 16/18 Bivalent Vaccine (Hansenula polymorpha,Jiangsu RecBio Technology）
Drug Alias NameRecombinant HPV bivalent (Types 16/18) vaccine (Alum）重组二价（16，18）HPV疫苗（铝佐剂）REC-601
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPapillomavirus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Rec-Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAbzymo Biosciences Co LtdJiangsu Rec-Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsPapillomavirus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A